Estradiol/progesterone

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Vanished user 0x8cSXE0x6 (talk | contribs) at 19:13, 27 November 2016. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Estradiol/progesterone
Combination of
EstradiolEstrogen
ProgesteroneProgestogen
Clinical data
Routes of
administration		Oral
Legal status
Legal status
Identifiers
CompTox Dashboard (EPA)

Estradiol/progesterone (developmental code name TX-001HR, formerly TX-12-001HR) is an oral combination of estradiol, an estrogen, and progesterone, a progestogen, that is under development by TherapeuticsMD for the treatment of menopausal symptoms and endometrial hyperplasia.[1][2] It is currently in phase III clinical trials for these indications.[1] The drug is the first combination of estradiol and progesterone that has been developed for clinical use.[2]

References

  1. ^ a b http://adisinsight.springer.com/drugs/800038089
  2. ^ a b Pickar JH, Bon C, Amadio JM, Mirkin S, Bernick B (2015). "Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy". Menopause. 22 (12): 1308–16. doi:10.1097/GME.0000000000000467. PMC 4666011. PMID 25944519.

External links


Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Estradiol/progesterone&oldid=751769428"